Anti-CD20 Monoclonal Antibody (Rituximab) for Therapy of Mediastinal CD20-Positive Large B-Cell Non-Hodgkin Lymphoma with a Local Tumor Extension into the Lung of a 10-Year-Old Girl

Čulić, Srdjana; Čulić, Viktor; Armanda, Višnja; Kuljiš, Dubravka; Pešutić-Pisac, Valdi; Janković, Stipan

doi:10.1080/08880010390203125

Cited by 18 publications

(2 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The number of patients with large B‐cell lymphoma was too small to properly address the impact of rituximab in this population, but, by contrast to BL, rituximab appears to improve large B‐cell lymphoma outcome at relapse in this series as in other pediatric reports …”

Section: Discussionmentioning

confidence: 99%

Outcome of relapse in children and adolescents with B‐cell non‐Hodgkin lymphoma and mature acute leukemia: A report from the French LMB study

Rigaud

Aupérin

Jourdain

et al. 2019

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Introduction In order to describe relapsed B‐cell non‐Hodgkin lymphoma and mature acute leukemia in children/adolescents treated with the Lymphomes Malins B (LMB) regimen and their outcome in the rituximab era, relapses in the French LMB2001 study were reviewed. Methods Between February 2001 and December 2011, 33 patients out of 773 (4.3%) relapsed; 27 had Burkitt lymphoma and six large B‐cell histology. Median age at diagnosis was 10.1 years. One patient was initially treated in risk group A, 21 in group B, and 11 in group C. Results Median time to relapse after diagnosis was 4.5 months (range 2.4‐13.6). Thirty‐two patients received salvage therapy. Twenty‐seven received rituximab mainly in addition to high‐dose cytarabine and etoposide (n = 18) and/or ifosfamide, carboplatin, and etoposide (n = 7). First‐line salvage chemotherapy response rate was 66% with 47% being complete remission (CR). Twenty‐one patients received high‐dose chemotherapy (HDC) followed by autologous (n = 13) or allogeneic (n = 8) transplant. With a median follow‐up of 6.8 years, the 5‐year survival rate after relapse was 36.4% (95% confidence interval [CI] 22‐53%). Twelve patients were still alive; all but one (group A) received consolidation treatment. Achieving CR before consolidation was significantly associated with better survival, with a 5‐year survival rate of 75% (95% CI 46.8‐91.1%) for patients in CR before HDC, 33% (95% CI 9.7‐70%) for patients in partial remission, and 0% for nonresponders (P = .033). Conclusion Survival of children/adolescents with mature B‐cell lymphoma/leukemia remains poor after relapse with no apparent improvement with rituximab. Response rates to salvage chemo‐immunotherapies are insufficient and new drugs are urgently needed to improve disease control.

show abstract

Section: Discussionmentioning

confidence: 99%

Outcome of relapse in children and adolescents with B‐cell non‐Hodgkin lymphoma and mature acute leukemia: A report from the French LMB study

Rigaud

Aupérin

Jourdain

et al. 2019

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…Relapsed or refractory B-NHL has a poor prognosis. CD20 is expressed in >98% of childhood B-NHL and increasingly a chimeric anti-CD20 monoclonal antibody, rituximab, is being used at relapse (7,8). Although rituximab is commonly used as a first-line therapy in adults, the effect of rituximab in children with B-NHL has yet to be adequately investigated (9-12).…”

mentioning

confidence: 99%

Rituximab used in three cases with relapsed non-Hodgkin’s lymphoma

Elli

Yılmaz

Aydin

et al. 2013

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Relapsed or refractory B-cell non-Hodgkin's lymphoma (B-NHL) patients have a poor prognosis. New treatment modalities have been used to improve survival rates in children with relapsed or refractory B-NHL. CD20 is expressed in >98% of childhood B-NHL and a chimeric anti-CD20 monoclonal antibody, rituximab, is increasingly being used at relapse. The aim of the present study was to determine the efficacy of rituximab on relapsed B-NHL. Three B-NHL cases were treated successfully with a combination of intensive chemotherapy protocol plus rituximab. IntroductionLymphomas are the third most common type of cancer identified during childhood and adolescence, with 60% of those being mature B-cell non-Hodgkin's lymphoma (B-NHL). Primary central nervous system malignant lymphomas (PCNSLs) comprise <2% of malignant lymphomas. B-NHL is usually of B-cell origin (1-4). First-line chemotherapy is found to be effective in the majority of children diagnosed with B-NHL. Although long-term cure rates are 75% for high-risk disease (5), relapses occur in ~20% of the patients, almost always within a year from diagnosis (6). Relapsed or refractory B-NHL has a poor prognosis. CD20 is expressed in >98% of childhood B-NHL and increasingly a chimeric anti-CD20 monoclonal antibody, rituximab, is being used at relapse (7,8). Although rituximab is commonly used as a first-line therapy in adults, the effect of rituximab in children with B-NHL has yet to be adequately investigated (9-12). Three B-NHL cases were investigated in this case study to determine the efficacy of rituximab-containing regimens on relapsed B-NHL. Case reportsPatient 1. A 16-year-old male was admitted to the Department of Pediatric Oncology complaining of recurrent abdominal pain and distention for the previous 2 months. Physical examination revealed that the abdomen was distended but non-tender, with an immobile, painless and hard mass, 5x8 cm in diameter, located on the right side of the abdomen. Results of bone marrow (BM) examination, hematologic and basic metabolic analysis were normal. Abdominal computed tomography (CT) scan confirmed multiple retroperitoneal lymph nodes and a mass, 6x10x11 cm in a diameter, surrounding the superior mesenteric artery (Fig. 1A). Burkitt lymphoma was diagnosed. Positive CD20, CD10, bcl6 and negative CD30, CD3, CD5 and TdT were reported by immunohistochemical examination. After 4 months of NHL-Berlin-Frankfurt-Muenster (BFM) 95 chemotherapy protocol, the patient noted backache. BM examination revealed diffuse L3 type lymphoblasts. Additionally, the CT scan showed that the size of the intra-abdominal mass did not decrease. The patient received intravenous rituximab (375 mg/m 2 /dose/once every 3 weeks) for six doses and Ifosfamide, Carboplatin and Etoposide (ICE). The control CT scan revealed that the size of the mass decreased and central necrosis was evident (Fig. 1B). Although in complete remission at least 12 months following chemotherapy, the patient succumbed due to systemic progression of severe sepsis.Patient 2. A 14-y...

show abstract

Rituximab, an Anti‐CD20 Monoclonal Antibody

Pescovitz

2010

Immunotherapy in Transplantation

View full text Add to dashboard Cite

Anti-CD20 Monoclonal Antibody (Rituximab) for Therapy of Mediastinal CD20-Positive Large B-Cell Non-Hodgkin Lymphoma with a Local Tumor Extension into the Lung of a 10-Year-Old Girl

Cited by 18 publications

References 8 publications

Outcome of relapse in children and adolescents with B‐cell non‐Hodgkin lymphoma and mature acute leukemia: A report from the French LMB study

Outcome of relapse in children and adolescents with B‐cell non‐Hodgkin lymphoma and mature acute leukemia: A report from the French LMB study

Rituximab used in three cases with relapsed non-Hodgkin’s lymphoma

Rituximab, an Anti‐CD20 Monoclonal Antibody

Contact Info

Product

Resources

About